icon-folder.gif   Conference Reports for NATAP  
 
  HEPDART 2013: Frontiers in Drug Development for Viral Hepatitis
December 8-12, 2013
Big Island, Hawaii
Back grey_arrow_rt.gif
 
 
 
A Fixed-Dose Combination of Sofosbuvir and Ledipasvir Is Highly Effective in Treatment-Naïve and Treatment-Experienced Genotype 1 HCV-Infected Patients: Results From the LONESTAR and ELECTRON Phase 2 Studies - poster
 
 
  Reported by Jules Levin
HEP DART 2013, December 8-12, 2013, Big Island, HI, USA
 
AASLD: Gilead at AASLD: Sofosbuvir for GT 3, 2 and 1 - (11/18/13)
 
AASLD: Gilead at AASLD: 2 - (11/18/13)
 
AASLD: Summary from AASLD 2013 for Hepatitis C Washington 1-5 November 2013 - Written by Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany - (12/02/13)
 
AASLD: BMS at AASLD - (11/18/13)
 
64rd Annual Meeting of the American Association for the Study of Liver Diseases Washington, DC Nov 1-5 2013
 
Eric Lawitz,1,2 Catherine Stedman,3 Fred F. Poordad,1,2 Phillip S. Pang,4 Xiao Ding,4 Robert H. Hyland,4 William T. Symonds,4 Fernando E. Membreno,1,2 Edward Gane5 1Texas Liver Institute, San Antonio, TX; 2University of Texas Health Science Center, San Antonio, TX; 3Christchurch Clinical Studies Trust, Christchurch, New Zealand; 4Gilead Sciences, Inc., Foster City, CA; 5Auckland Clinical Studies, Auckland, New Zealand

AASLD1.gif

AASLD2.gif

AASLD3.gif

AASLD4.gif

AASLD5.gif

AASLD6.gif

AASLD7.gif

AASLD8.gif

AASLD9.gif

AASLD10.gif